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Saturated fatty acids (SFAs) (the ‘‘bad’’ fat), especially
palmitate (PA), in the human diet are blamed for
potential health risks such as obesity and cancer
because of SFA-induced lipotoxicity. However,
epidemiological results demonstrate a latent benefit
of SFAs, and it remains elusive whether a certain
low level of SFAs is physiologically essential for main-
taining cell metabolic hemostasis. Here, we demon-
strate that although high-level PA (HPA) indeed in-
duces lipotoxic effects in liver cells, low-level PA
(LPA) increases mitochondrial functions and allevi-
ates the injuries induced by HPA or hepatoxic agent
carbon tetrachloride (CCl4). LPA treatment in mice
enhanced liver mitochondrial activity and reduced
CCl4 hepatotoxicity with improved blood levels of
aspartate aminotransferase (AST), alanine transami-
nase (ALT), and mitochondrial aspartate transami-
nase (m-AST). LPA-mediated mitochondrial homeo-
stasis is regulated by CDK1-mediated SIRT3
phosphorylation, which in turn deacetylates and di-
merizes CPT2 to enhance fatty acid oxidation. Thus,
an advantageous effect is suggested by the con-
sumption of LPA that augments mitochondrial meta-
bolic homeostasis via CDK1-SIRT3-CPT2 cascade.
INTRODUCTION
Overconsumption of fat in the human diet, especially saturated
fatty acids (SFAs) such as palmitate (PA), is associated with lip-
otoxicity-related disorders including obesity, cancer, cardio-
vascular diseases, diabetes, and nonalcoholic fatty liver dis-Deeases (NAFLD) (Forouhi et al., 2014; Mota et al., 2016; Xu
et al., 2006). However, unreasonable limitations on SFA intake
may be detrimental to normal cellular function, especially for
mitochondrial integrity and metabolic homeostasis. Increasing
evidence indicates that the connection between SFA consump-
tion and SFA-induced health risks should be reconsidered
based on epidemiological studies of energy-consumption-
associated health menaces (Mancini et al., 2015; Willett et al.,
2014). In fact, SFAs have been exonerated of blame for all-
cause mortality in cardiovascular diseases, ischemic stroke,
or type 2 diabetes (T2D) (de Souza et al., 2015; Lee et al.,
2008). A recent study of 27,296 adults from 8 European coun-
tries, including 12,132 T2D cases, demonstrates a reduced inci-
dence of T2D in people with increased intake of individual fatty
acids (FAs) (Imamura et al., 2017). Based on these findings, it
has been strongly suggested that SFA-associated cardiovas-
cular risk should be reevaluated (Siri-Tarino et al., 2010), and
a revision of global dietary guidelines has been suggested (Deh-
ghan et al., 2017). The Practice Guideline Committee of the
American Association for the Study of Liver has cautioned
that polyunsaturated FAs may promote alcohol-induced liver
disease whereas consumption of SFAs is potentially protective
(O’Shea et al., 2010). A diet high in fat and low in carbohydrates,
with exercise, has been recommended for reversing NAFLD
(Noakes and Windt, 2017). A cluster of endogenous lipids with
antidiabetic and anti-inflammatory functions is found to contain
PA isomers including palmitic-acid-9-hydroxy-stearic-acid
(Yore et al., 2014). Among other potential benefits, PA is known
to increasemembrane fluidity and glucosemetabolism to inhibit
hepatocellular carcinoma (Lin et al., 2017). These results,
together with our epidemiological analysis on correlations of
SFA-associated disease burden and motility (Table S1), sug-
gest that although overconsumption of SFAs indeed causes lip-
otoxicity, consumption of a certain level of SFAs appears to be
necessary for mitochondrial metabolism and normal cellular
function.velopmental Cell 52, 1–14, January 27, 2020 ª 2019 Elsevier Inc. 1
Figure 1. LPA Promotes Mitochondrial Homeostasis
(A) Status of SFA energy consumption in 113 countries in 1990, 2005, and 2010.
(B) Correlation of the burden of liver cirrhosis (defined as in [B]) related to alcohol use and all other pathogenic factors (hepatitis B and C and all other causes) with
the percentage of energy derived from SFAs, based on theWHO’s 2015 report on the Global Burden of Liver Cirrhosis (http://www.who.int/en) and Global Dietary
Database (https://www.globaldietarydatabase.org/).
(C) The burden of all-cause liver cirrhosis is reduced by consumption of a certain range of SFAs (7%–10%) compared to either lower or higher consumption levels.
Data points show the distribution of liver-cirrhosis-specific disability-adjusted life year (DALY) per 100,000 population aged 50 years and older in populations from
113 countries (mean ± SEM, *p < 0.05; **p < 0.01; ns, no significance).
(D) Schematic of the experiments characterizing the mitochondrial function and cell viability of mouse liver AML12 cells treated with a PA concentration gradient.
(legend continued on next page)
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man health requiring efficient energy dynamics for carrying out
the fundamental cellular functions (Berardi and Chou, 2014; Gra-
ier et al., 2009; Senyilmaz et al., 2015). However, lipotoxicity-
induced accumulation of PA especially in non-adipose cells
could be a result of experimentally impairing mitochondrial
oxidative capacity (Geng et al., 2015; Leamy et al., 2014). Such
PA-mediated lipotoxic effects are usually generated by a range
of high PA concentrations applied in both in vitro and in vivo
study models (Table S2). Thus, although such HPA models
have generated relevant information to mimic clinical lipotoxic
effects, they may cause us to overlook a potential advantageous
function of a physiological level of PA that is required in the eval-
uation of SFA-associated health issues. PA is the first product
during FA synthesis and the major precursor for the generation
of long-chain FAs, which are required for many fundamental
cellular functions, such as palmitoylation to enhance the hydro-
phobicity and determine the localization of proteins (Linder and
Deschenes, 2007). Therefore, defining a physiological level of
PA required for maintaining mitochondrial homeostasis in non-
adipose cells especially in liver will provide critical information
for optimizing a well-balanced energy intake to prevent lipotox-
icity-associated diseases.
SIRT3, primary mitochondrial deacetylase, plays a critical
role in maintaining mitochondrial metabolic homeostasis via
deacetylation of mitochondrial proteins (Qiu et al., 2010;
Wang et al., 2019; Winnik et al., 2015; Yang et al., 2016). An
array of key mitochondrial metabolic factors are under the
SIRT3 regulation, including complex I (Brenmoehl and Hoe-
flich, 2013), manganese superoxide dismutase (MnSOD) (Tao
et al., 2010), and isocitrate dehydrogenase 2 (Yu et al.,
2012). Recently, a MnSOD-K68 acetylation mimic mutant
that blocks SIRT3-mediated deacetylation is linked with pro-
carcinogenesis (Zhu et al., 2019). SIRT3-mediated mitochon-
drial homeostasis is achieved via preserving the balance be-
tween bioenergetic output and clearance of the reactive oxy-
gen species (ROS) (Ozden et al., 2011; Yu et al., 2012). FAs
are transferred from the cytoplasm into the mitochondrial ma-
trix by the carnitine O-palmitoyltransferases CPT1 and 2 (Cor-
bet et al., 2016) for the synthesis of ketone bodies through
fatty acid oxidation (FAO) and the trichloroacetic acid (TCA)
cycle. SIRT3 is shown to regulate the activity of long-chain
acyl coenzyme A dehydrogenase (LCAD) in FAO (Hirschey
et al., 2010) and is required for ameliorating hepatic lipotoxic-
ity (Bao et al., 2010). In addition, CDK1 activates SIRT3 (Liu
et al., 2015) and regulates mitochondrial protein influx and bio-
energetics (Harbauer et al., 2014; Wang et al., 2014). These
findings contribute to the hypothesis that the CDK1-SIRT3-
FAO pathway could be essential for the potential metabolic
benefits induced by consumption of a low level of SFAs.
This study reveals an advantageous mitochondrial
homeostasis in low-level PA (LPA)-treated mouse liver cells(E) Mitochondrial activities including ATP generation, OCR, MnSOD activity, Dcm
indicated concentration for 48 h. Data were presented as the percentage of the c
*p < 0.05; **p < 0.01, ***p < 0.001, ****p < 0.0001 versus BSA; ns, no significance
(F) Mitochondrial proteomics of AML12 cells measured 48 h after LPA (25 mM) tre
bioinformatics, proteins in FA metabolism and redox balance were marked in red
See also Figures S1–S3.with CRISPR-edited gene deficiency and in vivo mouse hepa-
totoxicity. LPA boosts mitochondrial metabolism and en-
hances the capacity to defend lipotoxicity in liver cells or
carbon tetrachloride (CCl4)-induced mouse hepatotoxicity.
SIRT3 is activated by CDK1-mediated phosphorylation in
mitochondria followed by SIRT3-mediated deacetylation and
dimerization of CPT2. Thus, LPA generates a favorable effect
in liver cells via the CDK1-SIRT3-CPT2 cascade.
RESULTS
LPA Promotes Mitochondrial Homeostasis and Limits
Hepatotoxic Injury
Referring to theWorld Health Organization (WHO) recommenda-
tion and study-based suggestion (Dehghan et al., 2017) for a
standard SFA consumption level (7%–10%, marked green in
Figure 1A), we used the Global Dietary Database (https://www.
globaldietarydatabase.org/) to estimate the correlation between
consumption level of SFAs and the disease burden of liver
cirrhosis (Figures 1B and 1C) as well as the mortality from other
lipotoxicity-related diseases (Figure S1). The burden of liver
cirrhosis from all causes (alcohol use, pathogenic factors, hepa-
titis B and C, and all other causes) was reduced in populations
with SFA energy intake between 7%and 10% compared to pop-
ulations with SFA intake of either >10% or <7% (Figures 1B and
1C; Table S1). The mortality of major lipotoxicity-related disease
was indeed increased with the level of SFA-based energy intake
>10%; however, no difference in mortality was detected in pop-
ulationswith SFA consumption of 7%–10%and <7% (Figure S1).
Referring to HPA being used to induce lipotoxicity to mimic clin-
ical observations of SFA overconsumption, cellular response to
the increased PA (R100 mM) and lowered PA (<100 mM) concen-
trations as well as animal tests on the liver response to a PA-en-
riched high-fat diet (HFD) were summarized in Table S2, which
was used to estimate the HPA and LPA concentrations in
this study.
Regarding the lipotoxicity-associated major human diseases
and mortality, our epidemiological analyses revealed a potential
undiscovered benefit by consumption of a certain low level of
SFA. We thus assumed that consumption of PA at a certain
low level may benefit cellular metabolism especially in non-adi-
pose cells such as liver cells that play the fundamental roles in
lipid metabolism. Following this line of reasoning, we investi-
gated mitochondrial function and cell viability in mouse liver
AML12 cells exposed to a gradient of PA concentrations (0–
1,000 mM) for 24 h and 48 h (Figure 1D). Indeed, HPA-induced lip-
otoxicity was recapitulatedwith reducedmitochondrial functions
including ATP generation, oxygen consumption rate (OCR),
MnSOD activity, membrane potential (Dcm), and cell viability
treated with HPA (>250 mM), and mitochondrial O2
 increased
proportionally with PA concentration (Figure 1E). In contrast,
no detectable mitochondrial dysfunction was observed in cells, O2
, and cell viability were measured in AML12 cells treated with PA at the
ontrol after normalization to the samples with BSA 0.05%. n = 3, mean ± SEM,
. LPA treatment for 24 h is shown in Figure S2A.
atment versus cells treated with 0.05% BSA. Data were categorized by DAVID
.
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Figure 2. LPA Pre-exposure Prevents Mito-
chondrial Injury Induced by HPA or CCl4
(A) Mitochondrial ATP, OCR, MnSOD activity,
Dcm, O2
, and cell viability measured in AML12
cells pretreated with BSA or LPA for 48 h, followed
by HPA (500 mM) for 24 h n = 3, mean ± SEM, *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus
HPA.
(B) Morphological alterations of AML12 cells
treated with BSA (Ctrl), HPA, or HPA plus pre-
treatment with LPA. Scale bar, 100 mm.
(C) Oil red O staining of AML12 cells pretreated
with BSA (Ctrl) or LPA for 48 h followed by BSA or
free fatty acids (FFAs) (oleic acid [OA]:PA = 2:1) for
24 h. Scale bar, 100 mm.
(D) Western blotting of mitochondrial or cyto-
plasmic proteins of AML12 cells treated in (A). Cyt
C, cytochrome C; COX IV, mitochondrial loading
control.
(E) Mass and integrity analysis of mitochondria of
AML12 cells treated as in (A). Upper panel, fluo-
rescence microscopy images of GFP-labeled
mitochondria (Mito-GFP; nuclear membrane is
indicated with a dashed red line). Quantification of
mitochondrial mass with ImageJ; n = 30, mean ±
SEM versus HPA, **p < 0.01, ***p < 0.001 (scale
bar, 4 mm). Lower panel, transmission electron
microscopic (TEM) images of mitochondrial ultra-
structure (mitochondrial membrane is indicated
with red arrows [scale bar, 500 nm]).
(F) Mitochondrial function and cell viability were
measured in AML12 cells treated with LPA fol-
lowed by CCl4 exposure (10 mM) for 3 h. n = 3,
mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001 versus CCL4.
See also Figure S4.
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ity, and Dcm were enhanced by 35%, 30%, 58%, and 24%,
respectively, with a corresponding reduction in mitochondrial
O2
 and increased cell viability, in cells treated with 25 mM PA
(this PA concentration was determined as the LPA for liver cells;
Figures 1E and S2A). Similarly, the LPA-boosted mitochondrial
functions were also observed in primary cultured mouse liver
cells (Figure S2B). In addition, liquid chromatography mass
spectrometry (LC/MS)-based proteomic analysis of LPA-treated
AML12 cells further revealed about 170 proteins involved in
LPA-induced reprogramming of mitochondrial metabolism and
homeostasis (Figure 1F). These proteins were involved in FAO,
redox metabolism, and oxidative phosphorylation (OXPHOS)
(Figures 1F and S3) that appeared to be different from the key
pathways induced in vivo response following a diet with high cal-
ories from fat (Table S3), supporting a potential LPA benefit via a
unique signaling pathway.
LPA Alleviates Mitochondrial Injury Induced by HPA
We then wondered if such LPA-enhanced mitochondrial activity
could be defensive against the lipotoxic effects induced by over-
consumption of SFAs. AML12 cells and primary mouse liver cells
were pretreated with LPA for 48 h and then challenged with a
dose of HPA (500 mM). Surprisingly, the entire index of mitochon-4 Developmental Cell 52, 1–14, January 27, 2020drial functions tested was improved by LPA with reduced O2

levels and increased cell viability (Figures 2A and S4A). However,
the boosted levels of mitochondrial activity appeared to be time
dependent. LPA pretreatment for 24 h did not enhance MnSOD
activity, cell viability, and FAO, although ATP generation, OCR,
Dcm, and O2
 levels were improved (Figures S4B and S4C).
Consistently, accumulated free fatty acids (FFAs) and severe
cellular damage were detected in cells treated with HPA,
whereas LPA pretreatment prevented such changes (Figure 2B)
and reduced FFAs (Figure 2C), suggesting that LPA-pretreated
liver cells are able to attenuate lipid accumulation with an
increased FAO capacity. LPA was also shown to prevent HPA-
induced cytochrome C release from mitochondria (Figure 2D),
with well-maintained mitochondrial mass, number, and struc-
tural integrity compared with the cells treated with HPA alone
(Figure 2E).
LPA Reduces Mitochondrial Injury and Alleviates
Hepatotoxicity Induced by CCl4
We next asked whether LPA-enhanced mitochondrial function
could also be protective against ROS-mediated mitochondrial
injury and hepatotoxicity. Mitochondrial function and cell viability
were measured in AML12 cells with or without LPA pretreatment
following exposure to CCl4, a well-studied toxic agent that
Figure 3. LPA Boosts Mitochondrial Activity
and Reduces CCl4-Induced Liver Injury
(A) Mitochondrial functions of primary liver cells
isolated from control and LPA-, CCl4-, and LPA/
CCl4-treated mice. n = 8, mean ± SEM, *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001, versus
CCL4;
#p < 0.05, ##p < 0.01 versus Ctrl.
(B) Blood levels of AST, ALT, and mitochondrial
AST (m-AST) in the animals of control, LPA, CCl4,
and LPA and CCl4 groups. n = 8, mean ± SEM, *p <
0.05, ***p < 0.001, ****p < 0.0001 versus CCL4,
#p <
0.05 versus Ctrl.
(C) Images of CCl4-induced inflammatory infiltra-
tion and necrotic lesions in liver tissue (H&E
staining and quantification, top) and mitochondrial
damage (TEM, bottom) in livers frommice from the
control, LPA, CCl4, and LPA/CCl4 groups. The
necrotic lesions in H&E staining were analyzedwith
ImageJ software, and the mitochondrial structural
integrity was scored by mitochondrial area per
hepatocyte, mm2. Top scale bar, 40 mm; bottom
scale bar, 500 nm. n = 8, mean ± SEM, *p < 0.05;
**p < 0.01, ***p < 0.001 versus CCL4.
See also Figure S5.
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et al., 2009). As expected, exposure to CCl4 decreased ATP gen-
eration, MnSOD activity, Dcm, and cell viability and elevated
levels of mitochondrial O2
; however, all of these changes
were significantly ameliorated in cells pretreated with LPA (Fig-
ure 2F). Using GFP-labeledmitochondrial proteins and transmis-
sion electron microscopy, we showed that mitochondrial mass
and ultrastructural integrity weremarkedly protected in LPA-pre-
treated cells compared to the control cells without LPA pretreat-
ment (Figure S4D).
LPA-mediated hepatoprotective function was then tested us-
ing the established mouse model of CCl4-induced acute liver
injury (Morales-Garza et al., 2017). The most effective in vivo
PA concentration was determined based on tests in mice
showing that intragastric gavage with 0.5 mg/mL of PA, but not
5.0 mg/mL or 100 mg/mL, increased mitochondrial Dcm and
reduced O2
 in the liver (Figure S5A). Thus, 0.5 mg/mL PA was
applied as the in vivo LPA. The optimized concentration of
CCl4 was also established by exposure of mice to 100%, 50%,
and 10% solutions of CCl4 (Figures S5B and S5C). The grade
of hepatotoxicity and mitochondrial injury were then assessed
in mice pretreated by intragastric gavage with 0.5 mg/mL PA
for 3, 6, and 12 days, followed by treatment with 100%CCl4 (Fig-
ure S5G). Remarkably, mice receiving the pretreatment of LPA
for 12 days significantly reduced the degree of mitochondrial
damage induced by CCl4 measured by ATP generation, MnSOD
activity, Dcm, and mitochondrial O2
 (Figure 3A). The mice
showed no significant alterations in blood levels of alanine trans-
aminase (ALT) and mitochondrial aspartate transaminase (m-
AST) in response to in vivo LPA treatment, though aspartateaminotransferase (AST) was slightly lowered (Figure 3B). How-
ever, the rise in blood levels of ALT, AST, and m-AST triggered
by CCl4 (127%, 41%, and 553%, respectively) was markedly
lowered in LPA-pretreated mice (Figure 3B). No obvious alter-
ations in body weight and liver weight were observed in any
group of mice (Figures S5D and S5E). LPA-mediated liver pro-
tection was further demonstrated by the inhibition of inflamma-
tory infiltration in the CV (central veins) area in the liver tissues
(Figure 3C, top) and well-preserved mitochondrial structure
and cristae (Figure 3C, bottom). In addition, no PA accumulation
was detected in the livers of LPA-pretreated mice (Figure S5F).
Interestingly, mice with LPA administration for 3 and 6 days did
not show noticeable LPA-mediated protection against CCl4-
mediated hepatotoxicity and metabolic damage (Figures S5H
and S5I). Together with the in vitro data showing less protection
by LPA pretreatment at 24 versus 48 h (Figure S4B), these results
indicate that a lag time is required for LPA to induce mitochon-
drial protection. In mice, a period of 12 days of LPA administra-
tion seems to be required to provide a protective effect.
CDK1 Boosts SIRT3 Activity in LPA-Induced
Reprogramming of Mitochondrial Metabolism
We and others have previously reported that CDK1 functions as
a sensor for cellular energy demand and mitochondrial bioener-
getics (Harbauer et al., 2014; Qin et al., 2015; Wang et al., 2014).
Here, we found that cyclin B1, the partner of CDK1 for CDK1
activation, and the activated form of CDK1 (phosphorylated at
T161; pCDK1-T161) were increased in the mitochondria of
cells treated with LPA for 48 h but decreased in themitochondria
of cells incubated with HPA (Figures 4A and S6A). To determineDevelopmental Cell 52, 1–14, January 27, 2020 5
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involved in LPA-promoted mitochondrial homeostasis, mito-
chondria-directed wild-type (WT) CDK1 and kinase-deficient
CDK1were separately transfected into AML12 cells (Figure S6B).
Expression of mitochondria-directed WT CDK1 but not the ki-
nase-deficient mutant enhanced mitochondrial function and
cell viability (Figures 4B and S6C). In CCl4 hepatotoxic tests (Fig-
ure 4C), surprisingly, pCDK1-T161 was totally abolished in the
liver mitochondria of mice treated with CCl4 alone, but a sub-
stantial amount of pCDK1-T161 and cyclin B1 were preserved
in the liver mitochondria of mice pretreated with LPA for
12 days before CCl4 administration (Figure 4D).
Mitochondrial homeostasis is linked to the regulation of
SIRT3, a well-defined mitochondrial deacetylase (Kim et al.,
2010; Tao et al., 2010) that attenuates PA-induced ROS (Koyama
et al., 2011). SIRT3 activity can be upregulated by CDK1 by irra-
diation (Liu et al., 2015). As expected, mitochondrial ATP pro-
duction and OCR were enhanced 50% and 56%, respectively,
in AML12 cells harboring WT SIRT3 and reduced 33% and
91%, respectively, in cells expressing the mutant of SIRT3-
T8A/S17A (Figure 4E). Information on the SIRT3 double mutant
and other mitochondrial functions including Dcm, O2
 and cell
viability were shown in Figure S6F. A direct interaction between
CDK1 and SIRT3 was detected in AML12 cells and was remark-
ably boosted by LPA treatment (Figure 4F). To determine
whether the SIRT3 phosphorylation is also enhanced by LPA,
immunoprecipitation (IP) was conducted first with an anti-phos-
pho-S and T antibody, followed by immunoblotting with anti-
SIRT3 antibody, demonstrating that phosphorylated SIRT3
was noticeably elevated by LPA pretreatment for both 24 and
48 h. At the same time, the acetylation level of mitochondrial pro-
teins was reduced by 24 and 48 h LPA incubation, confirming
that incubation of AML12 cells with LPA activates SIRT3 (Fig-
ure 4G). This result again supports the pattern of time-dependent
LPA-mediated mitochondrial homeostasis.
In vivo tests also demonstrated a striking enhancement of
CDK1-SIRT3 complex formation (Figure 4H) and a remarkable
elevation of phosphorylated SIRT3 (Figure 4I) in mice pretreated
with LPA for 12 days. Levels of pCDK1-T161 and acetylated
mitochondrial proteins showed a dependence on the duration
of the pretreatment with LPA, with the greatest difference at
12 days (Figure 4J). Although reduced acetylation of mitochon-
drial proteins and enhanced pCDK1-T161 were observed in
the livers of mice treated with LPA for 3 and 6 days (Figure 4J),
recall that no detectable improvement in blood levels of ALT
and AST were observed at these time points (Figures S5G and
S5H), indicating that a lag period is required for full enhancement
of liver mitochondrial function via LPA-mediated SIRT3 activa-
tion. Together, these results clearly demonstrate that LPA can
promote adaptive mitochondrial metabolism and homeostasis
via CDK1-mediated SIRT3 activation.
CPT2 Is Deacetylated and Activated Following CDK1-
SIRT3 Activation
Following the finding of LPA-mediated activation of the CDK1-
SIRT3 pathway, we then determined the potential key enzymes
in mitochondrial FAO. SIRT3 is shown to regulate mitochondrial
FAO (Hirschey et al., 2010) and required for ameliorating hepatic
lipotoxicity (Bao et al., 2010). CPT2 has been indented to be a6 Developmental Cell 52, 1–14, January 27, 2020critical FAO enzyme located on the inner mitochondrial mem-
brane (Figure S6G) (Hsiao et al., 2006). Although CPT2 was not
in the list of the LPA-enhanced profile by proteomics analysis
(Figures 1F and S3A), and the protein level was not enhanced
(Figure 5A), LPA increased the CPT2 enzymatic activity by
60% when measured by a 14C-radiochemical assay. Refer-
encing the reported SIRT3-mediated deacetylation residues
(Tao et al., 2010; Zhu et al., 2019), two potential deacetylation
candidate residues lysine 453 and 457 (K453 and 457) in CPT2
were predicted by SWISS-MODEL (Figures S6G–S6I). Direct
interaction of SIRT3 and CPT2 was detected and strikingly
enhanced by LPA (Figure 5B), and the acetylated form of CPT2
was also reduced (Figure 5B). Furthermore, this result was reca-
pitulated in mouse liver pretreated with LPA (Figure 5C). Thus,
both in vitro and in vivo results demonstrate that SIRT3-mediated
CPT2 deacetylation is involved in LPA-induced mitochondrial
metabolism.
To verify that SIRT3 is specifically phosphorylated by CDK1
in LPA-mediated mitochondrial enhancement, we constructed
lentiviral vectors expressing WT murine SIRT3, mutant SIRT3-
T8A, mutant SIRT3-S17A, and double mutant SIRT3-T8A/S17A
in AML12 cells (Figures 5D, S6D, and S6E). Interestingly,
compared to cells expressing WT SIRT3, the acetylated CPT2
was not enhanced in cells expressing SIRT3-T8A, but cells
harboring the SIRT3-S17A or SIRT3-T8A/S17A constructs
showed increased CPT2 acetylation (Figure 5D), indicating that
S17 of SIRT3 is specifically required for SIRT3-mediated CPT2
deacetylation.
Again, to determine whether the phosphorylation of SIRT3
at S17 is critical for CPT2 activation, CRISPR/Cas9-edited
SIRT3 knockout cells (SIRT3-KO; clone CRISPR#1, Figure 5E;
targeting sequences shown in Table S4) were reconstituted
with WT SIRT3 or SIRT3-S17A, showing that the SIRT3 mutation
at S17 (S to A) significantly increased the acetylation of CPT2
(Figure 5F), indicating that S17 is required for SIRT3-mediated
CPT2 deacetylation. Moreover, CPT2 activity, which decreased
by 59% in SIRT3-KO cells, was completely rescued (104%) by
re-expressing WT SIRT3. In contrast, the rescuing capacity
was severely hampered in cells transfected with the SIRT3-
S17A or SIRT3-T8A/S17A mutants (Figure 5G).
SIRT3-MediatedCPT2Dimerization Is Required for LPA-
Enhanced FAO
CPT1A is a carnitine-acylcarnitine translocase locating within the
mitochondrial outer membrane. It self-assembles into an oligo-
meric complex and catalyzes the rate-limiting step in the trans-
port of long-chain acyl-CoAs. CPT1A and CPT2 share 50%
homology. We thus speculated that CPT2 functions as an
oligomer enhanced by SIRT3-mediated deacetylation. Impor-
tantly, two potential acetylation sites K453 and K457 were
located (Figure S6G) with p values of 0.0009 and 0.0299, respec-
tively, (http://bioinfo.bjmu.edu.cn/huac/predict_p/) and highly
conserved across species (Figure S6H). To test whether K453
and K457 are required for the dimerization of CPT2, AML12 cells
were transfected with a lentivirus expressing v5-tag-linked
CPT2, and as expected, via native gel analysis, a band close
to twice the expected size of CPT2 (68 kDa) was detected in con-
trol cells and remarkably enhanced by LPA pretreatment (Fig-
ure 6A). The role of deacetylation of K453 and K457 was then
Figure 4. LPA Enhances Mitochondrial Homeostasis via CDK1-Mediated SIRT3 Activation
(A) Total and mitochondrial cyclin B1 and activated CDK1 (pCDK1-T161) in AML12 cells treated with LPA for 24 and 48 h.
(B) ATP and OCR measured in AML12 cells transfected with the mitochondria-targeted wild-type (WT) or kinase-deficient (mut) CDK1. n = 3, mean ± SEM, *p <
0.05, **p < 0.01, ***p < 0.001 versus vector; #p < 0.05, ###p < 0.001 versus MTS-CDK1 wt.
(C) Experimental design for detecting the CDK1-SIRT3 pathway in mouse livers treated with LPA. The procedures for LPA gavage, CCl4 injury, and mitochondrial
preparation from mouse livers were the same as in Figure S5A.
(D) Western blotting of mitochondrial cyclin B1 and pCDK1-T161 from pooled liver tissues of mice in the control, LPA, CCl4, and LPA/CCl4 groups. Right, relative
levels of pCDK1-T161 were quantified by ImageJ. n = 4, mean ± SEM. ***p < 0.001.
(E) ATP andOCR of AML12 cells transfectedwithWT or double mutant SIRT3-T8A/S17A. n = 3, mean ± SEM, *p < 0.05, **p < 0.01 versus vector. ##p < 0.01, ###p <
0.001 versus SIRT3 WT.
(F) Enhanced interaction between CDK1 and SIRT3 was detected by immunoprecipitation (IP) in mitochondrial fractions of LPA-treated AML12 cells. IB,
immunoblot.
(G) Phosphorylated SIRT3 and acetylated proteins of mitochondrial fractions were detected in AML12 cells treated with or without LPA. Acetylated mitochondrial
proteins were quantified by ImageJ. n = 4, mean ± SEM, **p < 0.01, ***p < 0.001.
(H) Interaction between CDK1 and SIRT3 in liver tissues of control and LPA-treated mice.
(I) Phosphorylated SIRT3 proteins detected in liver mitochondria of LPA-treated mice.
(J) pCDK1-T161 and acetylated proteins in liver mitochondria of mice treated with LPA for 0, 3, 6, and 12 days. Acetylated mitochondrial proteins were quantified
by ImageJ. n = 4, mean ± SEM, **p < 0.01, ***p < 0.001 versus day 0.
See also Figure S6.
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Figure 5. SIRT3 S17 Phosphorylation Is
Required for Deacetylation and Activation
of CPT2
(A) Enzymatic activity was measured by radio-
chemical assay in LPA-treated AML12 cells. n = 3,
mean ± SEM, **p < 0.01. Lower panel, western blot
showing the equal expression of CPT2 using COX
IV as the mitochondrial protein marker.
(B) Interaction between SIRT3 and CPT2 (left) and
reduced CPT2 acetylation (right) were detected in
AML12 cells treated with LPA or control solution.
(C) Interaction between SIRT3 and CPT2 (left) and
CPT2 acetylation (middle) were detected in pri-
mary mouse liver cells treated with LPA or control
solution. CPT2 acetylation was quantified by Im-
ageJ (right). n = 4, mean ± SEM, ***p < 0.001 versus
Ctrl.
(D) Left, schematic illustration of site-specific mu-
tations of SIRT3: Thr8/ Ala8, Ser17/ Ala17, or
Thr8/ Ser17/ Ala8 and Ala17 using a site-directed
mutagenesis kit (New England BioLabs Inc, Cat#
E0554). Right, the expression level of acetylated
CPT2 detected in AML12 cells expressingwild-type
SIRT3, SIRT3-T8A or SIRT-S17A mutant, or SIRT3-
T8A/S17A double mutants. In ImageJ quantitation,
n = 4, mean ± SEM, **p < 0.01 versus Ctrl.
(E) Western blotting of SIRT3 in AML12 cells with
two CRISPR/Cas9-mediated SIRT3 knockouts.
CRISPR #1 (mSIRT3 #1 guide RNA) was used for
subsequent experiments.
(F) Acetylated CPT2 proteins detected in SIRT3-KO
AML12 cells rescued with wild-type SIRT3 (WT) or
SIRT3-S17A mutant.
(G) CPT2 enzymatic activity measured by radio-
chemical assay in CRISPR/Cas9 SIRT3-KO AML12
cells re-expressing WT and mutant SIRT3 treated
by LPA. The re-expressed proteins of wild-type
SIRT3 (SIRT3 WT), SIRT3-T8A, SIRT-S17A, or
SIRT3-T8A/S17A were verified by western blot of
SIRT3 and b-actin as the loading control. n = 3,
mean ± SEM, *p < 0.05, **p < 0.01 versus Ctrl.
See also Figure S6 and Table S4.
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sgRNA-targeting sequences were shown in Table S4) with
expression of WT CPT2 or mutants K453Q, K457Q, or K453Q
and K457Q (Figures 6C and S6I). SIRT3-mediated CPT2 dimer-
ization was indicted by a strong band of the v5-tag near 150 kDa
detected in CRISPR-KO CPT2 cells reconstituted with v5-tag
WT CPT2. However, such dimerization was greatly reduced in
cells expressing CPT2-K453Q or CPT2-K457Q, where Q
mimicked the constitutive acetylation that blocks deacetylation
(Park et al., 2016), and absent in cells expressing the double
CPT2-K453Q and K457Q mutant. In contrast, the dimerized
CPT2 was enhanced in CPT2 cells with CPT2-K453R, K457R,
or K453R and K457R with the Q-R mutation that enhances de-
acetylation (Figure 6D). CPT2 enzymatic activity measured by a
14C-radiochemical assay further demonstrated that the 38%
CPT2 activity remaining in the CPT2-KO cells was completely
restored by expressing WT CPT2 and could be further enhanced
by expression of deacetylation-mimic CPT2 mutants (K453R,
K457R, or K453R/K457R). In consistence, WT CPT2 mediated
restoration of CPT2 activity was absent in CPT2-KO cells recon-
stituted with acetylation mimics but restored in the deacetylation
mimics (Figure 6E). Furthermore, FAO-driven oxygen consump-8 Developmental Cell 52, 1–14, January 27, 2020tion (Figure 6F) andmitochondrial ATP generation and OCR (Fig-
ure 6G) were completely enhanced by reconstitution ofWTCPT2
but absent in the acetylation mimics. The CPT2 deacetylation
mimics were also shown to be able to enhance mitochondrial
metabolism (ATP generation, OCR, MnSOD activity, Dcm, and
O2
) and cell viability in the absence of CDK1 and SIRT3 (Figures
S6J–S6L). Collectively, these data provide the experimental ev-
idence indicating that CPT2 K453/K457 are the sites of SIRT3-
mediated CPT2 activation, which is required for CPT2 dimeriza-
tion in LPA-induced mitochondrial metabolic enhancement.
DISCUSSION
In contrast to the popular conception of SFAs as deleterious to
human health, this study reveals a beneficial effect induced by
LPA on mitochondrial function and liver welfare. We report
here that LPA promotes adaptive mitochondrial homeostasis
that is able to ameliorate mitochondrial injuries induced by sub-
sequent exposure to HPA or exposure to the hepatoxic agent
CCl4. In the CCl4 mouse hepatotoxicity model, LPA-mediated
adaptive mitochondrial activation lessens CCl4-mediated liver
injury with improved blood levels of ALT, AST, and m-AST.
Figure 6. SIRT3-Mediated CPT2 Dimeriza-
tion and Activation via Deacetylation at
K453 and K457
(A) Enhanced CPT2 dimerization in AML12 cells
transfected with v5-tag-labeled CPT2 and treated
with LPA for 48 h. In ImageJ analysis, n = 4, mean ±
SEM.
(B) Western blot of CPT2 in CRISPR/Cas9-edited
CPT2 KO AML12 cells. CRISPR-2 with a complete
CPT2 knockout was selected for subsequent ex-
periments.
(C) Western blot of CPT2 in CPT2 KO cells recon-
stituted with v5-tag-labeled wild-type CPT2 (CPT2
WT), mutants K453Q or K457Q, or double mutant
K453Q/K457Q.
(D) Formation of CPT2 homodimers in CRISPR-
CPT2 knockout cells rescued with wild-type CPT2,
mutants K453Q, K457Q, K453Q/K457Q or K453R,
K457R, K453R/K457R that mutated back from
K453Q, K457Q and K453Q/K457Q, respectively.
Homodimers were quantified with ImageJ and
normalized to a-tubulin, n = 4, mean ± SEM, **p <
0.01, ***p < 0.001, ****p < 0.0001 versus CPT2 WT.
(E) CPT2 enzymatic activity as measured by 14C
radiochemical assay in LPA-treated cells
compared with CPT2 knockout (KO) cells rescued
with wild-type CPT2, mutants K453Q, K457Q,
K453Q/K457Q or K453R, K457R, K453R/K457R
that mutated back from K453Q, K457Q, and
K453Q/K457Q, respectively. n = 3, mean ± SEM,
*p < 0.05, **p < 0.01, ***p< 0.001 versus Ctrl.
(F) FAO-driven oxygen consumption was
measured in LPA-treated CPT2 KO cells and the
KO cells re-expressed WT or mutant (K453Q,
K457Q, or K453Q/K457Q) CTP2. The uncoupler
FCCP [Carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone] was used to induce maximal
electron transport chain activity by dissipating
Dcm. Signal and signal control (Ctrl) were used to
show the probe signal in the absence of cellular
respiration.
(G) ATP and OCR in LPA-treated CRISPR-CPT2
knockout AML12 cells rescued with wild-type (WT)
CPT2 or K453Q/K457Q mutant. n = 3, mean ± SEM, *p < 0.05 versus vector; ##p < 0.01, ###p < 0.001 versus CPT2 WT.
(H) CDK1-SIRT3-CPT2 cascade in LPA-promoted mitochondrial homeostasis. Findings from this study demonstrate a unique mechanismwherein mitochondrial
homeostasis is maintained by a low concentration of PA (LPA). LPA enhances CDK1, which upregulates SIRT3 in mitochondria via Ser17 phosphorylation. CPT2
activity is then boosted by SIRT3-mediated deacetylation of CPT2 at K453/K457, causing CPT2 dimerization to accelerate CPT2 activity and FAO. OM, outer
membrane; IM, inner membrane.
See also Figure S6 and Table S4.
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meostasis are revealed by uncovering two post-translational
modifications in a unique CDK1-SIRT3-CPT2 cascade in which
CDK1 activates SIRT3 via T8 and S17 phosphorylation that in
turn leads to dimerization and activation of CPT2 via SIRT3-
mediated CPT2 K453/K457 deacetylation (schematic presenta-
tion in Figure 6H).
Our present study sheds light on a long-held debate over the
potential risk by consumption of SFAs (Nettleton et al., 2016).
Reduction of dietary SFAs is recommended, although no evi-
dence is indicated with SFA-mediated risk in cardiovascular dis-
ease. A possible reason for the overlooked pro-homeostatic
benefit of SFAs is likely due to the comprehensive epidemiologic
studies on SFA-related health risks and lipotoxic diseases asso-
ciated with consumption of high-level SFAs (Kim et al., 2015;Kurahashi et al., 2008; Sellem et al., 2019). These studies were
conducted with SFAs as a part of a fat-heavy diet with a pro-
longed period such as the population-based analysis on SFA-
associated breast cancer risk (Sieri et al., 2014; Wakai et al.,
2005). Another reason for the potentially advantageous function
of SFAs being ignored may be the fact that ROS generated by
SFAs cause widespread damage in cells (Yanagisawa et al.,
2008). Therefore, it has been unclear whether an ideal physiolog-
ical SFA consumption level required for maintaining normal
mitochondrial and cellular function exists. Here, by lowering PA
to a certain level, we reveal an obvious favorable function of
PA for liver mitochondrial homeostasis. Compared to the
enhanced ROS accumulation generated by HPA, mitochondrial
superoxide is reduced with enhanced MnSOD, the major antiox-
idant enzyme in mitochondria, in LPA-mediated mitochondrialDevelopmental Cell 52, 1–14, January 27, 2020 9
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MnSOD protein expression in endothelial cells induced by PA
at 100 and 150 mM (Broniarek et al., 2016) that is consistent
with our current finding that 100 mM PA increased MnSOD enzy-
matic activity by20% (Figure 1E). Importantly, 25 mM seems to
be close to the physiological level, allowing AML12 cells to
achieve the maximal mitochondrial and cellular protection. The
doses near to 25 mM (12.5, 50, and 100 mM) also elevated
MnSOD activity with related mitochondrial O2
 alternations (Fig-
ure 1E). Such LPA-enhanced mitochondrial metabolism with
boosted Dcm, OCR, and ATP generation are consistent with
the findings that lowering the digestion of SFAs reduces health
risk (Bueno et al., 2013). A small number of epidemiological
studies of a low-fat diet (calories from fat <10%) show a benefit
in weight loss and significant reduction of blood pressure as
well as improving the ratio of total cholesterol to high-density li-
poprotein (HDL) cholesterol (Shai et al., 2008). SFA-mediated
cancer inhibition has also been demonstrated in human breast
cancer cells (Evans et al., 2009; Levi et al., 2015). However,
our current study revealed little improvement in mitochondrial
function in cells treated with the PA in the dose range of 0–
12.5 mM. These results seem to be consistent with the epidem-
ical data showing that populations with less than 7% fat energy
intake are no health benefit and, in most cases, an even worse
disease burden (Figures 1A–1C and S1; Table S1). Although
the exact definition of the physiology level of SFA consumption
for humans will continue to debate and define, health benefits
are evidenced by lowering fat intake (Tobias et al., 2015). Lieber
andDeCarli (1970) demonstrated that 10%of total dietary calorie
intake from FA, rather than either below or above such a level,
generates the least hepatic triglyceride accumulation in rat liver
(Lieber and DeCarli, 1970). A relative low-fat diet (<30% of en-
ergy) with 10% energy from SFAs is also recommended by
WHO (https://www.who.int/en/news-room/fact-sheets/detail/
healthy-diet), whereas dietary intake of <7% of energy from
SFAs may be harmful (Dehghan et al., 2017).
Mitochondrial protein deacetylation plays a critical role in cell
metabolism (DeMarchi et al., 2019; Peek et al., 2013). SIRT3 is a
NAD(+)-dependent deacetylase in the mitochondrial matrix to
regulate the acetylation levels of metabolic enzymes. Hirschey
et al. (2010) reported that LCAD is the metabolic substrate in
SIRT3-regulated FAO metabolism during animal fasting (Hir-
schey et al., 2010). The current study further reveals that
SIRT3-mediated dimerization is required for activation of
another key FAO enzyme CPT2 via SIRT3-mediated deacetyla-
tion. The enhancedmitochondrial homeostasis was achieved at
48 h in cell culture and 12 days in animal tests, indicating that
LPA exerts detectable cellular benefits in a time-dependent
manner. Consistently, a similar lag time has been demonstrated
in nutrition-derived cellular homeostasis (Morgan et al., 1998).
In AMPK-mediated mitochondrial metabolism, non-glucose
carbon sources limit mitochondrial biogenesis and OXPHOS
capacity (Chaube et al., 2015), suggesting that a lag time is
required for translating nutrition intake to detectable cellular
benefits (Wang et al., 2011). In the present study, both phos-
phorylation and acetylation are involved in the LPA-mediated
CDK1-SIRT3-CPT2 cascade, which may contribute to the lag
time for orchestrating the mitochondrial homeostasis. CDK
can regulate FA for cell cycle progression (Santos-Rosa et al.,10 Developmental Cell 52, 1–14, January 27, 20202005), phosphorylate Drp1 to control mitochondrial dynamics
(Tahbaz et al., 2011), and boost mitochondrial bioenergetics
(Wang et al., 2014) and protein influx (Harbauer et al., 2014)
for cell cycle progression. The mitochondrial CDK1, further
defined in the current study, is enhanced by LPA to augment
SIRT3 function via Thr8/Ser17 phosphorylation (Wang et al.,
2014). Thus, CDK1-mediated SIRT3 phosphorylation may pre-
sent the first rate-limiting step in LPA-promoted mitochondrial
homeostasis. SIRT3-mediated deacetylation and activation of
CPT2 may also contribute to the lag time for LPA-mediated
mitochondrial activation. In addition, the cluster of mitochon-
drial proteins including factors for redox balance and FA
metabolism detected from our proteomics analysis suggests
multiple metabolic mechanisms involved in LPA-mediated
mitochondrial function. Further elucidation of such pro-homeo-
static factors related to CDK1-SIRT3-CPT2 cascade will be
necessary to reveal more mechanistic insights in LPA-mediated
mitochondrial homeostasis.
The LPA-mediated protective function against the injuries
induced by HPA or CCl4 may have a critical clinical impact.
SIRT3 is the central regulator of mitochondrial homeostasis
(Newman et al., 2012) that can regulate FAO metabolism (Hal-
lows et al., 2011) and MnSOD activation (Tao et al., 2010) as
well as LCAD (Bharathi et al., 2013). Increased risk of developing
metabolic syndrome is observed in humans with a deficiency of
SIRT3 (Hirschey et al., 2011). The reported SIRT3-mediated
MnSOD activation (Tao et al., 2010) is also involved in the LPA-
mediated mitochondrial homeostasis probably due to the
requirement of detoxifying the enhanced O2
 level of FAO and
mitochondrial respiration. Thus, SIRT3-mediated MnSOD acti-
vation may play a key role in the LPA-mediated mitochondrial
protective function against lipotoxicity induced by HPA or the
hepatotoxic effect induced by CCL4.
SIRT3 is reported to be involved in FAO metabolism (Hirschey
et al., 2010). Additionally, two recent works are supportive to our
current findings, indicating the importance of fatty acid turnover
rate in the maintenance of human weight and health (Arner et al.,
2019) and the critical role of SIRT3 in controlling mitochondrial
metabolism via protein deacetylation (Wang et al., 2019). Our re-
sults further demonstrate that CPT2 is directly controlled by
SIRT3 in LPA-mediated mitochondrial homeostasis via deacety-
lation-controlled dimerization enzyme activity. CPT2 located in
the inner mitochondrial membrane functions in lipid mitochon-
drial transportation and oxidization, which is connected to the
TCA cycle and mitochondrial bioenergetics. CPT2-mediated
FA metabolism is demonstrated in an array of cellular functions
(Gonzalez-Hurtado et al., 2018; Xiong et al., 2018). Defects in
the CPT2 gene are associated with deficiency in mitochondrial
FAO and impair the functions of complexes I and V (Haorah
et al., 2013). SIRT3-mediated deacetylation is found to be neces-
sary for CPT2 dimerization and enzymatic activation. Such post-
translational modification of CPT2 in mitochondria does not
require gene transcription, and thus CPT2 protein levels are
not necessarily enhanced in LPA-treated cells. Thus, the
SIRT3-mediated deacetylation and dimerization of CPT2 indi-
cates a quick regulatory mechanism on FAO enhancement. In
addition, SIRT3-mediated CPT2 deacetylation and activation is
nonetheless related to the CPT1 activity that regulates the rate
of FA import into the mitochondria from the cytoplasm. The
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CPT2 in LPA-mediated mitochondrial FAO is to be further
elucidated.
In conclusion, this study uncovered an overlooked beneficial
effect of SFAs on mitochondrial homeostasis that alleviates
HPA-induced lipotoxic effect and CCL4-induced hepatotoxicity.
A unique pathway CDK1-SIRT3-CPT2 is identified in LPA-medi-
ated mitochondrial metabolic enhancement.SUPPORTING CITATIONS
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